JP2002537102A - 吸着された高分子および微粒子を有するミクロエマルジョン - Google Patents

吸着された高分子および微粒子を有するミクロエマルジョン

Info

Publication number
JP2002537102A
JP2002537102A JP2000600618A JP2000600618A JP2002537102A JP 2002537102 A JP2002537102 A JP 2002537102A JP 2000600618 A JP2000600618 A JP 2000600618A JP 2000600618 A JP2000600618 A JP 2000600618A JP 2002537102 A JP2002537102 A JP 2002537102A
Authority
JP
Japan
Prior art keywords
microemulsion
microparticles
adsorbed
group
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000600618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002537102A5 (https=
Inventor
デレック オハガン，
ギャリー エス． オット，
ジョン ドネリー，
ジナ カザズ，
ミルドレッド ウゴゾーリ，
マンモハン シンフ，
ジョン バラックマン，
Original Assignee
カイロン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27382688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2002537102(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by カイロン コーポレイション filed Critical カイロン コーポレイション
Publication of JP2002537102A publication Critical patent/JP2002537102A/ja
Publication of JP2002537102A5 publication Critical patent/JP2002537102A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Colloid Chemistry (AREA)
JP2000600618A 1999-02-26 2000-02-09 吸着された高分子および微粒子を有するミクロエマルジョン Withdrawn JP2002537102A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12185899P 1999-02-26 1999-02-26
US60/121,858 1999-02-26
US14639199P 1999-07-29 1999-07-29
US60/146,391 1999-07-29
US16199799P 1999-10-28 1999-10-28
US60/161,997 1999-10-28
PCT/US2000/003331 WO2000050006A2 (en) 1999-02-26 2000-02-09 Microemulsions with adsorbed macromoelecules and microparticles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011232182A Division JP6073053B2 (ja) 1999-02-26 2011-10-21 吸着された高分子および微粒子を有するミクロエマルジョン

Publications (2)

Publication Number Publication Date
JP2002537102A true JP2002537102A (ja) 2002-11-05
JP2002537102A5 JP2002537102A5 (https=) 2007-04-05

Family

ID=27382688

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2000600618A Withdrawn JP2002537102A (ja) 1999-02-26 2000-02-09 吸着された高分子および微粒子を有するミクロエマルジョン
JP2011232182A Expired - Lifetime JP6073053B2 (ja) 1999-02-26 2011-10-21 吸着された高分子および微粒子を有するミクロエマルジョン
JP2014110216A Withdrawn JP2014169323A (ja) 1999-02-26 2014-05-28 吸着された高分子および微粒子を有するミクロエマルジョン
JP2016125184A Pending JP2016172767A (ja) 1999-02-26 2016-06-24 吸着された高分子および微粒子を有するミクロエマルジョン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011232182A Expired - Lifetime JP6073053B2 (ja) 1999-02-26 2011-10-21 吸着された高分子および微粒子を有するミクロエマルジョン
JP2014110216A Withdrawn JP2014169323A (ja) 1999-02-26 2014-05-28 吸着された高分子および微粒子を有するミクロエマルジョン
JP2016125184A Pending JP2016172767A (ja) 1999-02-26 2016-06-24 吸着された高分子および微粒子を有するミクロエマルジョン

Country Status (9)

Country Link
US (4) US8206749B1 (https=)
EP (3) EP1156781B1 (https=)
JP (4) JP2002537102A (https=)
AT (1) ATE297190T1 (https=)
AU (1) AU2875700A (https=)
CA (2) CA2689696C (https=)
DE (1) DE60020677T2 (https=)
ES (2) ES2579783T3 (https=)
WO (1) WO2000050006A2 (https=)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524698A (ja) * 2003-04-25 2006-11-02 カイロン コーポレイション カチオン性微粒子およびｈｃｖｅ１ｅ２ｄｎａを含有する組成物ならびにその使用
JP2009514842A (ja) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントを含むスプリットインフルエンザワクチンにおけるｔｈ１／ｔｈ２バランスの変化
JP2010522206A (ja) * 2007-03-22 2010-07-01 ピーディーエス バイオテクノロジー コーポレイション カチオン脂質による免疫応答の刺激
JP2010524945A (ja) * 2007-04-18 2010-07-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア タンパク質で修飾されたナノ液滴、ならびにその合成物および製造方法
JP2013512892A (ja) * 2009-12-03 2013-04-18 ノバルティス アーゲー エマルジョンの微小流動化中および／または均質化中における成分の循環
JP2013531680A (ja) * 2010-07-06 2013-08-08 ノバルティス アーゲー カチオン性水中油型エマルジョン
JP2015521601A (ja) * 2012-06-15 2015-07-30 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ カチオン性脂質ワクチン組成物および使用方法
JP2017014229A (ja) * 2009-07-31 2017-01-19 ラモット アット テル アビブ ユニバーシティ， リミテッド ポリヌクレオチド剤を含む細胞標的化ナノ粒子およびその使用
US10638750B2 (en) 2004-05-20 2020-05-05 Eden Research Plc Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them
US10729130B2 (en) 2004-01-23 2020-08-04 Eden Research Plc Nematicidal compositions and methods of using them
JPWO2020246584A1 (https=) * 2019-06-06 2020-12-10
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP2023518519A (ja) * 2020-04-13 2023-05-01 四川大学 マイクロエマルションに基づくワクチン送達システム、その製造方法及び使用
US11801257B2 (en) 2008-04-17 2023-10-31 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
US11904015B2 (en) 2012-09-21 2024-02-20 Pds Biotechnology Corporation Vaccine compositions and methods of use
US12551460B2 (en) 2017-12-05 2026-02-17 Pds Biotechnology Coporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
MXPA03002640A (es) * 2000-09-28 2003-06-19 Chiron Corp Microparticulas para la distribucion de acidos nucleicos heterologos.
ATE350015T1 (de) * 2000-09-28 2007-01-15 Novartis Vaccines & Diagnostic Mikropartikelzusammensetzungen und verfahren zu ihrer herstellung
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
US6552004B1 (en) * 2000-10-30 2003-04-22 Universite De Montreal Delivery system for entrapping charged macromolecules and a method for preparing same
JP4188687B2 (ja) * 2000-12-27 2008-11-26 ダイナバックス テクノロジーズ コーポレイション 免疫変調ポリヌクレオチド及びその使用法
JP4607452B2 (ja) 2001-08-07 2011-01-05 ダイナバックス テクノロジーズ コーポレイション 免疫調節性組成物、製剤およびその使用方法
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
CN100354297C (zh) * 2001-10-03 2007-12-12 希龙公司 辅助的脑膜炎球菌组合物
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
JP2005508945A (ja) * 2001-10-06 2005-04-07 メリアル リミテッド Ｃｐｇ配合物及び関連方法
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
JP4726485B2 (ja) * 2002-08-02 2011-07-20 大日本住友製薬株式会社 細菌細胞壁骨格成分製剤
NZ538628A (en) * 2002-08-12 2008-06-30 Dynavax Tech Corp Immunomodulatory compositions, methods of making, and methods of use thereof
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
EP1631264B8 (en) 2003-06-02 2017-05-24 GlaxoSmithKline Biologicals SA Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
PT1861120T (pt) 2005-03-23 2016-08-18 Glaxosmithkline Biologicals Sa Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
CA2604392A1 (en) * 2005-04-11 2006-10-19 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
US8398983B2 (en) 2005-06-27 2013-03-19 Glaxosmithkline Biologicals, S.A. Immunogenic composition
JP2009504805A (ja) * 2005-08-09 2009-02-05 ナノバイオ コーポレーション 抗炎症活性を有するナノエマルジョン組成物
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
ES2420829T3 (es) * 2005-11-04 2013-08-27 Novartis Vaccines And Diagnostics S.R.L. Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
WO2007052061A2 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
PT2347775T (pt) 2005-12-13 2020-07-14 The President And Fellows Of Harvard College Estruturas em andaime para transplante celular
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
MX2008015529A (es) 2006-06-12 2009-01-13 Cytos Biotechnology Ag Procesos para empacar oligonucleotidos en particulas similares a virus de bacteriofagos de arn.
HRP20140488T1 (hr) 2006-07-17 2014-07-04 Glaxosmithkline Biologicals S.A. Cjepivo protiv influence
CA2671873C (en) 2006-12-12 2018-10-09 Brian Stephen Sproat Oligonucleotides containing high concentrations of guanine monomers
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US10328133B2 (en) * 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
WO2009123480A1 (en) * 2008-04-01 2009-10-08 Virionyx Corporation Ltd Anti-infective agents and uses thereof
EP2280690A2 (en) * 2008-04-18 2011-02-09 Nanobio Corporation Methods for treating herpes virus infections
WO2009131995A1 (en) 2008-04-21 2009-10-29 Nanobio Corporation Nanoemulsion influenza vaccine
WO2009132343A1 (en) * 2008-04-25 2009-10-29 Nanobio Corporation Nanoemulsions for treating onchomycosis
JP2011518844A (ja) 2008-04-25 2011-06-30 ナノバイオ コーポレーション 真菌、酵母および糸状菌感染症を治療するためのナノエマルション
AU2009248810B2 (en) 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
MX2010014026A (es) 2008-06-27 2011-02-15 Pfizer Composiciones adyuvantes novedosas.
EP2349209A2 (en) 2008-09-26 2011-08-03 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
WO2010092479A2 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with reduced amounts of squalene
BRPI1014031A2 (pt) * 2009-06-16 2018-02-20 Univ Michigan Regents vacinas de nanoemulsão
EP2461828B1 (en) 2009-07-31 2017-06-21 President and Fellows of Harvard College Programming of cells for tolerogenic therapies
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2506832B1 (en) 2009-12-03 2014-02-26 Novartis AG Hydrophilic filtration during manufacture of vaccine adjuvants
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
AU2013202706B2 (en) * 2009-12-03 2016-02-11 Seqirus UK Limited Circulation of components during microfluidization and/or homogenization emulsions
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
JP6104806B2 (ja) 2010-10-06 2017-03-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP2701745B1 (en) 2011-04-28 2018-07-11 President and Fellows of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
WO2012167230A1 (en) 2011-06-03 2012-12-06 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
CA2840965C (en) 2011-07-06 2021-03-02 Novartis Ag Cationic oil-in-water emulsions
SG10201605512WA (en) 2011-07-06 2016-09-29 Novartis Ag Oil-in-water emulsions that contain nucleic acids
US10206996B2 (en) * 2011-08-22 2019-02-19 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
ES2991989T3 (es) * 2012-03-23 2024-12-05 Macro Biologics Inc Composiciones y usos de materiales antimicrobianos con propiedades compatibles con tejidos
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CN104244929B (zh) 2012-04-16 2017-04-05 哈佛学院董事会 用于调节免疫反应的介孔二氧化硅组合物
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
KR101943171B1 (ko) 2013-09-19 2019-01-29 조에티스 서비시즈 엘엘씨 유성 아쥬반트
EP2851066A1 (en) * 2013-09-23 2015-03-25 LTS LOHMANN Therapie-Systeme AG Fixation of vaccine formulations on devices for epidermal immunisation by oily adjuvants
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
EP4112076A1 (en) 2014-10-10 2023-01-04 The Regents of The University of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
DK3244920T5 (da) 2015-01-16 2024-10-07 Zoetis Services Llc Mund- og klovsyge-vaccine
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
US11123740B2 (en) 2015-06-29 2021-09-21 Arizona Board Of Regents On Behalf Of Arizona State University Systems and methods for continuous flow digital droplet polymerase chain reaction bioanalysis
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP4286012A3 (en) 2015-09-17 2024-05-29 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US20180289792A1 (en) 2015-10-22 2018-10-11 ModernaTX. Inc. Sexually transmitted disease vaccines
CA3002912A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
HRP20220652T1 (hr) 2015-12-10 2022-06-24 Modernatx, Inc. Pripravci i postupci unosa terapijskih sredstava
HUE057877T2 (hu) 2015-12-22 2022-06-28 Modernatx Inc Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
RS63135B1 (sr) 2015-12-23 2022-05-31 Modernatx Inc Postupci upotrebe polinukleotida koji kodiraju ox40 ligand
US20190241658A1 (en) 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
EP3411475B1 (en) 2016-02-06 2025-08-27 President and Fellows of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
CA3026108A1 (en) 2016-06-10 2017-12-14 Clarity Cosmetics Inc. Non-comedogenic hair and scalp care formulations and method for use
CN115404196A (zh) 2016-07-13 2022-11-29 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
CN110418651A (zh) 2016-08-02 2019-11-05 哈佛学院院长等 用于调节免疫应答的生物材料
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
WO2018098438A1 (en) 2016-11-28 2018-05-31 Arizona Board Of Regents On Behalf Of Arizona State University Systems and methods related to continuous flow droplet reaction
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
US11969506B2 (en) 2017-03-15 2024-04-30 Modernatx, Inc. Lipid nanoparticle formulation
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
SMT202300097T1 (it) 2017-03-15 2023-05-12 Modernatx Inc Composto e composizioni per il rilascio intracellulare di agenti terapeutici
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
US11285189B2 (en) 2017-04-06 2022-03-29 Amicrobe, Inc. Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
US12220486B2 (en) 2018-03-02 2025-02-11 Saint Joseph's University Polymer compositions for storage and release of polypeptides
SG11202009478PA (en) 2018-04-02 2020-10-29 Dropworks Inc Systems and methods for serial flow emulsion processes
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
BR112022004936A2 (pt) 2019-09-19 2022-06-14 Modernatx Inc Compostos lipídicos contendo carbonato e composições para distribuição intracelular de agentes terapêuticos
AU2020350759A1 (en) 2019-09-19 2022-03-31 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
EP4405372A4 (en) 2021-09-22 2026-01-14 Hdt Bio Corp SARS-CoV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE
JP2024535354A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
KR20240096468A (ko) 2021-09-22 2024-06-26 에이치디티 바이오 코포레이션 감염병에 대한 rna 백신
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033487A1 (en) * 1997-01-30 1998-08-06 Chiron Corporation Use of microparticles with adsorbed antigen to stimulate immune responses
WO1998033932A1 (en) * 1997-01-31 1998-08-06 Korea Institute Of Science And Technology Lipid emulsions as gene transfection agents and method of preparing said emulsions
WO1999001579A1 (en) * 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
WO1999004761A1 (en) * 1997-07-22 1999-02-04 Pharmacia & Upjohn Ab Method of preparing pharmaceutical compositions of lipid particles comprising a lipid agent and a protein
WO1999030737A1 (en) * 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
WO2000006120A1 (en) * 1998-07-31 2000-02-10 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1565298A (en) 1925-12-15 Stop check announcing device for adding machines
CA583561A (en) 1959-09-22 H. Edgerton William Therapeutically valuable esters and methods for obtaining the same
US1573698A (en) 1922-06-21 1926-02-16 Union Carbide & Carbon Res Lab Denatured alcohol
US2800457A (en) 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
FR1317586A (https=) 1961-03-17 1963-05-08
NL134977C (https=) 1962-07-11
BE755269A (fr) 1969-08-25 1971-02-01 Westinghouse Electric Corp Systeme de regulation d'epaisseur du produit lamine sortant d'un laminoir
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4772466A (en) 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5324513A (en) 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
EP0175787B1 (en) 1984-04-06 1995-02-15 Chiron Corporation RECOMBINANT HERPES SIMPLEX gB-gD VACCINE
US5098704A (en) 1984-06-18 1992-03-24 Chiron Corporation Hepatitis surface antigen particle vaccine
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US4689225A (en) 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
US4826957A (en) 1985-07-12 1989-05-02 New York University Immunogenic recombinant yeast expression product and method for purifying it
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
ES2061500T5 (es) 1986-06-17 2003-05-16 Chiron Corp Diagnosis y vacunas de la hepatitis delta, su preparacion y uso.
DK341386D0 (da) 1986-07-18 1986-07-18 Voetman Karin Glassau Fremgangsmaade og apparat til oprulning af flade dejstykker, f.eks. til roulader
WO1988002634A1 (en) 1986-10-20 1988-04-21 Chiron Corporation Vaccine for use in the therapeutic treatment of hsv
DE3855807T2 (de) 1987-11-03 1997-06-12 Syntex (U.S.A.) Inc., Palo Alto, Calif. Einen Tetra-Polyol enthaltendes Impfstoff-Adjuvans
NZ227011A (en) 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
JP2607712B2 (ja) 1988-01-29 1997-05-07 カイロン コーポレイション 組換えｃｍｖ中和タンパク
KR0185373B1 (ko) 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
DK0398748T3 (da) 1989-05-18 2002-03-18 Chiron Corp NANBV-diagnostika: polynukleotider anvendelige til screening for hepatitis C virus
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
CH679207A5 (https=) 1989-07-28 1992-01-15 Debiopharm Sa
FI925835A0 (fi) * 1990-06-29 1992-12-22 Chiron Corp Vacciner innehaollande liposomer
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
WO1994012158A1 (en) 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JPH0827018A (ja) 1994-07-22 1996-01-30 Sanwa Kagaku Kenkyusho Co Ltd 生理活性ペプチド又は蛋白質を含有する薬剤組成物
US5672584A (en) 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5736392A (en) 1995-06-07 1998-04-07 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
GB9514285D0 (en) 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
US5814516A (en) 1995-10-13 1998-09-29 Lockheed Martin Energy Systems, Inc. Surface enhanced Raman gene probe and methods thereof
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
GB9608803D0 (en) 1996-04-27 1996-07-03 Univ Newcastle Mitochondrial dna defects
US5912332A (en) 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
US5821060A (en) 1996-08-02 1998-10-13 Atom Sciences, Inc. DNA sequencing, mapping, and diagnostic processes using hybridization chips and unlabeled DNA
ATE243761T1 (de) 1996-10-04 2003-07-15 Dako As Sonden zur detektion von mycobakterien
DE19640974A1 (de) 1996-10-04 1998-04-16 Bayer Ag Bausteine für DNA/PNA-Cooligomere
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
GB9621367D0 (en) 1996-10-14 1996-12-04 Isis Innovation Chiral peptide nucleic acids
WO1998020162A2 (en) 1996-11-05 1998-05-14 Clinical Micro Sensors Electrodes linked via conductive oligomers to nucleic acids
US5800999A (en) 1996-12-16 1998-09-01 Tropix, Inc. Dioxetane-precursor-labeled probes and detection assays employing the same
CA2228875A1 (en) 1997-02-08 1998-08-08 Boehringer Mannheim Gmbh A method for the preparation of nucleic acid binding compound
US5962230A (en) 1997-02-13 1999-10-05 The University Of Connecticut Diagnosis and treatment of glaucoma
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE19712530A1 (de) 1997-03-25 1998-10-01 Boehringer Mannheim Gmbh Neue Monomerbausteine zur Markierung von peptidischen Nukleinsäuren
AU6769998A (en) 1997-03-26 1998-10-20 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
WO1998055495A2 (en) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP1006999A2 (en) * 1997-07-08 2000-06-14 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
US6045816A (en) * 1998-06-17 2000-04-04 Isp Investments Inc. Water-based microemulsion of a pyrethroid
AU763975B2 (en) 1998-07-29 2003-08-07 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
KR100701569B1 (ko) 2006-07-10 2007-03-29 주식회사 경동나비엔 응축방지를 위한 저장식 보일러의 열교환기 구조
EP2019117A1 (en) 2007-07-27 2009-01-28 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Optimized purification process of recombinant growth factor protein
US8804125B2 (en) 2010-03-12 2014-08-12 Konica Minolta, Inc. Detection method for intermolecular interaction and detection device thereof
JP6136343B2 (ja) 2012-06-12 2017-05-31 株式会社リコー 情報処理システム、情報処理方法、プログラム、及び記録媒体
AT514720B1 (de) 2013-08-30 2016-03-15 Blum Gmbh Julius Stellvorrichtung
CN104683216B (zh) 2013-11-29 2019-04-12 腾讯科技（深圳）有限公司 客服信息的转发方法及装置、客服系统
JP6287387B2 (ja) 2014-03-12 2018-03-07 株式会社リコー 液滴吐出装置の液体粘度検出方法、液滴吐出装置の制御方法、液滴吐出装置、及び液滴吐出装置の液体粘度を検出する回路
FR3030069B1 (fr) 2014-12-16 2020-03-20 Zrc Geneve Sa Montre a lunette tournante
KR102354328B1 (ko) 2015-09-22 2022-01-21 삼성전자주식회사 영상 표시 장치 및 그 동작 방법
US9680022B1 (en) 2016-07-12 2017-06-13 United Microelectronics Corp. Semiconductor device having silicon-germanium layer on fin and method for manufacturing the same
JP2020112507A (ja) 2019-01-16 2020-07-27 日本電信電話株式会社 案内文生成装置、案内システム、案内文生成方法及びプログラム

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033487A1 (en) * 1997-01-30 1998-08-06 Chiron Corporation Use of microparticles with adsorbed antigen to stimulate immune responses
WO1998033932A1 (en) * 1997-01-31 1998-08-06 Korea Institute Of Science And Technology Lipid emulsions as gene transfection agents and method of preparing said emulsions
WO1999001579A1 (en) * 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
WO1999004761A1 (en) * 1997-07-22 1999-02-04 Pharmacia & Upjohn Ab Method of preparing pharmaceutical compositions of lipid particles comprising a lipid agent and a protein
WO1999030737A1 (en) * 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
WO2000006120A1 (en) * 1998-07-31 2000-02-10 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524698A (ja) * 2003-04-25 2006-11-02 カイロン コーポレイション カチオン性微粒子およびｈｃｖｅ１ｅ２ｄｎａを含有する組成物ならびにその使用
US10729130B2 (en) 2004-01-23 2020-08-04 Eden Research Plc Nematicidal compositions and methods of using them
US10638750B2 (en) 2004-05-20 2020-05-05 Eden Research Plc Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them
JP2009514842A (ja) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントを含むスプリットインフルエンザワクチンにおけるｔｈ１／ｔｈ２バランスの変化
JP2010522206A (ja) * 2007-03-22 2010-07-01 ピーディーエス バイオテクノロジー コーポレイション カチオン脂質による免疫応答の刺激
US11911359B2 (en) 2007-03-22 2024-02-27 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
JP2014058525A (ja) * 2007-03-22 2014-04-03 Pds Biotechnology Corp カチオン脂質による免疫応答の刺激
JP2010524945A (ja) * 2007-04-18 2010-07-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア タンパク質で修飾されたナノ液滴、ならびにその合成物および製造方法
US11801257B2 (en) 2008-04-17 2023-10-31 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
JP2017014229A (ja) * 2009-07-31 2017-01-19 ラモット アット テル アビブ ユニバーシティ， リミテッド ポリヌクレオチド剤を含む細胞標的化ナノ粒子およびその使用
US10179113B2 (en) 2009-07-31 2019-01-15 Ramot At Tel-Aviv University Ltd. Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
JP2013512892A (ja) * 2009-12-03 2013-04-18 ノバルティス アーゲー エマルジョンの微小流動化中および／または均質化中における成分の循環
KR101523215B1 (ko) * 2009-12-03 2015-05-27 노파르티스 아게 에멀션 미세 액화 및/또는 균질화 동안 성분들의 순환
JP2013531680A (ja) * 2010-07-06 2013-08-08 ノバルティス アーゲー カチオン性水中油型エマルジョン
JP2015521601A (ja) * 2012-06-15 2015-07-30 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ カチオン性脂質ワクチン組成物および使用方法
US12201685B2 (en) 2012-06-15 2025-01-21 Pds Biotechnology Corporation Methods of modulating immune responses with cationic lipid vaccine compositions
US11911465B2 (en) 2012-09-21 2024-02-27 Pds Biotechnology Corporation Vaccine compositions and methods of use
US11904015B2 (en) 2012-09-21 2024-02-20 Pds Biotechnology Corporation Vaccine compositions and methods of use
US11638753B2 (en) 2015-11-13 2023-05-02 PDS Biotechnology Corporalion Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US12551460B2 (en) 2017-12-05 2026-02-17 Pds Biotechnology Coporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
WO2020246584A1 (ja) * 2019-06-06 2020-12-10 デンカ株式会社 ペプチド核酸を基盤としたアジュバント
US12016920B2 (en) 2019-06-06 2024-06-25 Denka Company Limited Adjuvant based on peptide nucleic acid
JP7602457B2 (ja) 2019-06-06 2024-12-18 デンカ株式会社 ペプチド核酸を基盤としたアジュバント
JPWO2020246584A1 (https=) * 2019-06-06 2020-12-10
JP2023518519A (ja) * 2020-04-13 2023-05-01 四川大学 マイクロエマルションに基づくワクチン送達システム、その製造方法及び使用
JP7475733B2 (ja) 2020-04-13 2024-04-30 四川大学 マイクロエマルションに基づくワクチン送達システム、その製造方法及び使用
US12539272B2 (en) 2020-04-13 2026-02-03 Sichuan University Microemulsion-based vaccine delivery system, preparation method therefor and use thereof
KR102950449B1 (ko) * 2020-04-13 2026-04-09 시추안 유니버시티 마이크로에멀젼 기반 백신 전달 시스템 및 그 제조 방법, 용도

Also Published As

Publication number Publication date
EP1574210A2 (en) 2005-09-14
JP2016172767A (ja) 2016-09-29
EP1574210B1 (en) 2016-04-06
EP1574210A3 (en) 2007-02-21
CA2689696A1 (en) 2000-08-31
DE60020677T2 (de) 2006-05-04
EP1156781A2 (en) 2001-11-28
DE60020677D1 (de) 2005-07-14
US20070116709A1 (en) 2007-05-24
US20130195898A1 (en) 2013-08-01
JP2014169323A (ja) 2014-09-18
US20130195923A1 (en) 2013-08-01
WO2000050006A2 (en) 2000-08-31
EP2286792A1 (en) 2011-02-23
JP2012017344A (ja) 2012-01-26
CA2689696C (en) 2013-08-06
US8771747B2 (en) 2014-07-08
US8734832B2 (en) 2014-05-27
EP1156781B1 (en) 2005-06-08
US8309139B2 (en) 2012-11-13
WO2000050006A3 (en) 2001-01-18
CA2363141A1 (en) 2000-08-31
ES2242604T3 (es) 2005-11-16
JP6073053B2 (ja) 2017-02-01
ES2579783T3 (es) 2016-08-16
US8206749B1 (en) 2012-06-26
CA2363141C (en) 2010-04-06
ATE297190T1 (de) 2005-06-15
AU2875700A (en) 2000-09-14

Similar Documents

Publication Publication Date Title
JP6073053B2 (ja) 吸着された高分子および微粒子を有するミクロエマルジョン
US8541023B2 (en) Immunogenic compositions containing phospholipid
CA2528007C (en) Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
CA2420621C (en) Microparticle compositions and methods for the manufacture thereof
EP0991403B1 (en) Use of microparticles with adsorbed antigen to stimulate immune responses
US7501134B2 (en) Microparticles with adsorbed polypeptide-containing molecules
JP2002508334A (ja) サブミクロンの水中油型エマルジョンと合わせた微粒子の使用
PT1585542E (pt) Composições imunogénicas contendo fosfolípido

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100511

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100611

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100709

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100812

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111101

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111108

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20111216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120427

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120530

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120628

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120703

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120731